Site Announcement
Aethlon Medical is closely monitoring the Bird Flu situation and stands ready to work alongside hospitals, health agencies and the FDA if existing therapies prove inadequate.
Combating Cancer and Infectious Diseases with Immunotherapeutic Technologies
Aethlon Medical develops immunotherapeutic technologies to combat cancer and infectious disease. The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for 1) the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes and exosomal particles have been shown to participate in the development or severity of the disease; and 2) life-threatening viruses that are not addressed with approved therapies.
Aethlon Medical is currently conducting a safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solidtumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo®(nivolumab) in Australia and India. The primary endpoint of the approximately nine to 18-patient, safety, feasibility and dose-finding trial in each country is safety.